Bruno Holzvogt

Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)

M. Scholz, U. Platzbecker, S. Schwind, 2021, Journal of Cancer Research and Clinical Oncology.

Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)

D. Niederwieser, R. Krahl, S. Schwind, 2017, Journal of Cancer Research and Clinical Oncology.

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

G. Behre, D. Niederwieser, T. Lindner, 2014, Journal of Cancer Research and Clinical Oncology.

Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma

D. Niederwieser, S. Schwind, T. Lange, 2015, Journal of Cancer Research and Clinical Oncology.